Aclarion, Inc. (ACON)
NASDAQ: ACON · IEX Real-Time Price · USD
0.283
-0.011 (-3.61%)
May 2, 2024, 4:00 PM EDT - Market closed
Aclarion Revenue
In the year 2023, Aclarion had annual revenue of $75.40K with 24.75% growth. Revenue in the quarter ending December 31, 2023 was $13.80K, a -38.73% decrease year-over-year.
Revenue (ttm)
$75.40K
Revenue Growth
+24.75%
P/S Ratio
26.83
Revenue / Employee
$18,851
Employees
4
Market Cap
2.02M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 75.40K | 14.96K | 24.75% |
Dec 31, 2022 | 60.44K | 152.00 | 0.25% |
Dec 31, 2021 | 60.29K | 11.64K | 23.93% |
Dec 31, 2020 | 48.65K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionACON News
- 7 days ago - Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain - GlobeNewsWire
- 2 months ago - Aclarion Announces Closing of $3.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Aclarion Announces Pricing of $3.0 Million Public Offering - GlobeNewsWire
- 3 months ago - Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership - GlobeNewsWire
- 3 months ago - Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD - GlobeNewsWire
- 4 months ago - Aclarion Announces Reverse Stock Split - GlobeNewsWire
- 5 months ago - Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams - GlobeNewsWire
- 6 months ago - Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD - GlobeNewsWire